Neha Satish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neha Satish has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jeremiah J. Gassensmith
Department of Chemistry and Biochemistry University of Texas at Dallas Richardson Texas USA
3 shared publications Fabian C. Herbert
Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Rd. Richardson, TX 75080, United States
2 shared publications- Orikeda Trashi
Department of Chemistry and Biochemistry The University of Texas at Dallas 800 West Campbell Rd Richardson 75080 TX USA
2 shared publications - Sneha Kumari
Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080, United States
2 shared publications - Wendy Tang
Department of Chemistry and Biochemistry The University of Texas at Dallas 800 West Campbell Rd Richardson 75080 TX USA
2 shared publications Angelo A. Izzo
Centenary Institute/University of Sydney Royal Prince Alfred Hospital Building 93, Missenden Road Camperdown New South Wales 2050 Australia
1 shared publication
Latest Publications
- Open Access
Discovery of Surface‐Engineered Nanoparticles That Boost Enzyme Activity via High‐Throughput Screening and Machine Learning
Nanoparticles (NPs) are known to enhance the activity of enzymes, but such findings remain largely empirical, lacking predictive design principles. Here, the first high‐throughput platform for the discovery of surface‐engineered nanoparticles (SENs) that modulate enzyme function is introduced. Guided by the hypothesis that surface ligands are primary drivers of activity enhancement, a library of 194 gold‐ and palladium‐based SENs functionalized with diverse peptide ligands is synthesized. These SENs are screened against three model enzymes: cytochrome c, lactoperoxidase (LPO), and lipase. Multiple SENs substantially increased enzymatic activity, with the most effective achieving ≈19‐fold increase. The resulting dataset enabled the training of a machine learning model that identified key ligand features associated with high‐performing SENs, establishing a predictive framework for designing activity‐enhancing NPs. Mechanistic studies confirm that the ligand shell plays a dominant role in driving enhancement, suggesting that effective ligands identified via this approach can be readily transferred across NP platforms. To demonstrate functional relevance, it is shown that an optimized SEN/LPO pair outperforms LPO in inhibiting the growth of multidrug‐resistant bacteria and disrupting biofilm formation. Collectively, this work offers a scalable and generalizable method to map and harness nanoscale structure‐function relationships at biointerfaces, with applications in biocatalysis, biosensing, and beyond.
Open AccessDiscovery of Surface‐Engineered Nanoparticles That Boost Enzyme Activity via High‐Throughput Screening and Machine Learning
Nanoparticles (NPs) are known to enhance the activity of enzymes, but such findings remain largely empirical, lacking predictive design principles. Here, the first high‐throughput platform for the discovery of surface‐engineered nanoparticles (SENs) that modulate enzyme function is introduced. Guided by the hypothesis that surface ligands are primary drivers of activity enhancement, a library of 194 gold‐ and palladium‐based SENs functionalized with diverse peptide ligands is synthesized. These SENs are screened against three model enzymes: cytochrome c, lactoperoxidase (LPO), and lipase. Multiple SENs substantially increased enzymatic activity, with the most effective achieving ≈19‐fold increase. The resulting dataset enabled the training of a machine learning model that identified key ligand features associated with high‐performing SENs, establishing a predictive framework for designing activity‐enhancing NPs. Mechanistic studies confirm that the ligand shell plays a dominant role in driving enhancement, suggesting that effective ligands identified via this approach can be readily transferred across NP platforms. To demonstrate functional relevance, it is shown that an optimized SEN/LPO pair outperforms LPO in inhibiting the growth of multidrug‐resistant bacteria and disrupting biofilm formation. Collectively, this work offers a scalable and generalizable method to map and harness nanoscale structure‐function relationships at biointerfaces, with applications in biocatalysis, biosensing, and beyond.
- 18 December 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 193, 571-583
Dually functionalized dendrimer for stimuli-responsive release of active ingredients into the skin
- 18 December 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 193, 571-583
Dually functionalized dendrimer for stimuli-responsive release of active ingredients into the skin
- 8 December 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (26) , e2402358
Mn and Zn‐Doped Multivariate Metal–Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection
A first‐in‐class vaccine adjuvant delivery system, Mn‐ZIF, is developed by incorporating manganese (Mn) into the zinc‐containing zeolitic‐imidazolate framework‐8 (ZIF‐8). The mixed metal approach, which allowed for tunable Mn doping, is made possible by including a mild reducing agent in the reaction mixture. This approach allows up to 50% Mn, with the remaining 50% Zn within the ZIF. This multivariate approach exhibits significantly decreased cytotoxicity compared to ZIF‐8. The porous structure of Mn‐ZIF enables the co‐delivery of the STING agonist cyclic di‐adenosine monophosphate (CDA) through post‐synthetic loading, forming CDA@Mn‐ZIF. The composite demonstrated enhanced cellular uptake and synergistic activation of the cGAS‐STING pathway, producing proinflammatory cytokines and activating antigen‐presenting cells (APCs). In a preclinical Mycobacterium tuberculosis (Mtb) model, CDA@Mn‐ZIF formulates with the CysVac2 fusion protein elicited a potent antigen‐specific T‐cell response and significantly reduced the mycobacterial burden in the lungs of infected mice. These findings highlight the potential of CDA@Mn‐ZIF as a promising adjuvant for subunit vaccines, offering a novel approach to enhancing vaccine efficacy and protection against infectious diseases such as tuberculosis.
- 8 December 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (26) , e2402358
Mn and Zn‐Doped Multivariate Metal–Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection
A first‐in‐class vaccine adjuvant delivery system, Mn‐ZIF, is developed by incorporating manganese (Mn) into the zinc‐containing zeolitic‐imidazolate framework‐8 (ZIF‐8). The mixed metal approach, which allowed for tunable Mn doping, is made possible by including a mild reducing agent in the reaction mixture. This approach allows up to 50% Mn, with the remaining 50% Zn within the ZIF. This multivariate approach exhibits significantly decreased cytotoxicity compared to ZIF‐8. The porous structure of Mn‐ZIF enables the co‐delivery of the STING agonist cyclic di‐adenosine monophosphate (CDA) through post‐synthetic loading, forming CDA@Mn‐ZIF. The composite demonstrated enhanced cellular uptake and synergistic activation of the cGAS‐STING pathway, producing proinflammatory cytokines and activating antigen‐presenting cells (APCs). In a preclinical Mycobacterium tuberculosis (Mtb) model, CDA@Mn‐ZIF formulates with the CysVac2 fusion protein elicited a potent antigen‐specific T‐cell response and significantly reduced the mycobacterial burden in the lungs of infected mice. These findings highlight the potential of CDA@Mn‐ZIF as a promising adjuvant for subunit vaccines, offering a novel approach to enhancing vaccine efficacy and protection against infectious diseases such as tuberculosis.
- Open Access
- 29 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Mn and Zn-Doped Multivariate Metal-Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection
A first-in-class vaccine adjuvant delivery system, Mn-ZIF, was developed by incorporating manganese (Mn) into the zinc-containing zeolitic-imidazolate framework-8 (ZIF-8). The mixed metal approach, which allowed for tunable Mn doping, was made possible by including a mild reducing agent into the reaction mixture. This approach allowed up to 50% Mn, with the remaining 50% Zn within the ZIF. This multivariate approach exhibited significantly decreased cytotoxicity compared to ZIF-8. The porous structure of Mn-ZIF enabled the co-delivery of the STING agonist cyclic di-adenosine monophosphate (CDA) through post-synthetic loading, forming CDA@Mn-ZIF. The composite demonstrated enhanced cellular uptake and synergistic activation of the cGAS-STING pathway, producing proinflammatory cytokines and activating antigen-presenting cells (APCs). In a preclinical Mycobacterium tuberculosis (Mtb) model, CDA@Mn-ZIF formulated with the CysVac2 fusion protein elicited a potent antigen-specific T-cell response and significantly reduced the mycobacterial burden in the lungs of infected mice. These findings highlight the potential of CDA@Mn-ZIF as a promising adjuvant for subunit vaccines, offering a novel approach to enhancing vaccine efficacy and protection against infectious diseases such as tuberculosis.
- 29 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMn and Zn-Doped Multivariate Metal-Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection
A first-in-class vaccine adjuvant delivery system, Mn-ZIF, was developed by incorporating manganese (Mn) into the zinc-containing zeolitic-imidazolate framework-8 (ZIF-8). The mixed metal approach, which allowed for tunable Mn doping, was made possible by including a mild reducing agent into the reaction mixture. This approach allowed up to 50% Mn, with the remaining 50% Zn within the ZIF. This multivariate approach exhibited significantly decreased cytotoxicity compared to ZIF-8. The porous structure of Mn-ZIF enabled the co-delivery of the STING agonist cyclic di-adenosine monophosphate (CDA) through post-synthetic loading, forming CDA@Mn-ZIF. The composite demonstrated enhanced cellular uptake and synergistic activation of the cGAS-STING pathway, producing proinflammatory cytokines and activating antigen-presenting cells (APCs). In a preclinical Mycobacterium tuberculosis (Mtb) model, CDA@Mn-ZIF formulated with the CysVac2 fusion protein elicited a potent antigen-specific T-cell response and significantly reduced the mycobacterial burden in the lungs of infected mice. These findings highlight the potential of CDA@Mn-ZIF as a promising adjuvant for subunit vaccines, offering a novel approach to enhancing vaccine efficacy and protection against infectious diseases such as tuberculosis.